Any wrong or incomplete data? Any missing, misplaced, unlicensed picture? Please report any abuse, inaccuracy or lack of information to info@ticinoscienza.ch

1) Efficacy of Novel Bromodomain and Extraterminal Inhibitors in Combination with Chemotherapy for Castration-Resistant Prostate Cancer
European Urology Oncology, giugno 2021

2) Pharmacodynamic and Pharmacokinetic Properties of Full Phosphorothioate Small Interfering RNAs for Gene Silencing In Vivo
Nucleic Acid Therapeutics, giugno 2021

3) Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer
Cell Reports, 28 aprile 2015

4) Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity
Cell Reports, 9 ottobre 2014

5) Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Nature, 6 novembre 2014

6) Pharmacological inhibition of Lin28 promotes ketogenesis and restores lipid homeostasis in models of non-alcoholic fatty liver disease
Nature Communications, 26 dicembre 2022

7) A functional SNP regulates E-cadherin expression by dynamically remodeling the 3D structure of a promoter-associated non-coding RNA transcript
Nucleic Acids Research, 28 ottobre 2022

8) P1245 Polymorphic Variants of HSD3B1 Gene Confer Different Outcome in Specific Subgroups of Patients Infected With SARS-CoV-2
Frontiers in Medicine, 7 luglio 2022

9) Synthesis of Aminoethyl-Substituted Piperidine Derivatives as σ1 Receptor Ligands with Antiproliferative Properties
ChemMedChem, 5 aprile 2022

10) Lactate Rewires Lipid Metabolism and Sustains a Metabolic-Epigenetic Axis in Prostate Cancer
Cancer Research, 1 aprile 2022

11) Mitochondrial Plasticity Promotes Resistance to Sorafenib and Vulnerability to STAT3 Inhibition in Human Hepatocellular Carcinoma
Cancers, 30 novembre 2021

12) Inflammatory metabolic profile of South African patients with prostate cancer
Cancer & Metabolism, 3 agosto 2021

13) EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer
Nature Communications, 6 luglio 2021

14) Chemoenzymatic synthesis of 2,6-disubstituted tetrahydropyrans with high σ1 receptor affinity, antitumor and analgesic activity
European Journal of Medicinal Chemistry, 5 luglio 2021

15) Chemoenzymatic synthesis of 2,6-disubstituted tetrahydropyrans with high σ 1 receptor affinity, antitumor and analgesic activity
European Journal of Medical Chemistry, 20 aprile 2021

16) Circulating extracellular vesicles release oncogenic miR-424 in experimental models and patients with aggressive prostate cancer
Communications Biology, 26 gennaio 2021

17) Novel σ1 antagonists designed for tumor therapy: Structure - activity relationships of aminoethyl substituted cyclohexanes
European Journal of Medicinal Chemistry, 15 gennaio 2021

18) Erratum: Mapelli, S.N., et al. A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors). Cancers 2020, 12, 176
Cancers, 14 ottobre 2020

19) A Novel Prostate Cell Type-Specific Gene Signature to Interrogate Prostate Tumor Differentiation Status and Monitor Therapeutic Response (Running Title: Phenotypic Classification of Prostate Tumors)
Cancers, 10 gennaio 2020
Carlo Catapano
is currently collaborating with
Istituto Oncologico di Ricerca (IOR) (Rif. IOR)
Via Francesco Chiesa 5
6500 Bellinzona
Carlo Catapano
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently participating in the Research Group
Experimental Therapeutics
as Group Leader [Rif. 55110]
Carlo Catapano
on behalf of
Istituto Oncologico di Ricerca (IOR) USI (Rif. IOR)
is currently Research Program Leader [Rif. 50110] for
Tumor Biology and Experimental Therapeutics
Carlo Catapano
is Head of Research Programs [Rif. 20700]
at Istituto Oncologico di Ricerca (IOR) (Rif. IOR)
Via Francesco Chiesa 5 6500 Bellinzona